Neuroendocrinology Letters, Home
Contact us
Subscription info
Neuroendocrinology Letters incl. Psychoneuroimmunology & Chronobiology


ISSNİ0172ñ780X Copyrightİ©İ1998 NeuroendocrinologyİLetters

NEL Vol. 18 No. 1
Original Article

1998; 18:7-14
pii: NEL180197A02


Effects of PACAP, VIP and their peptide fragments on scopolamine-induced impaired performance and on the ChAT activity in the brain of rats

by Yoshimasa Yamaguchi, Masaya Higashi, Masahiro Nishio and Hidcshi Kobayashi

Research Laboratory, Zenyaku Kogyo Co., Ltd, 2-33-7, Ohizumi-machi, Nerima-ku, Tokyo 178, Japan

Received February 24. 1997


Pituitary adenylate cyclase-activating polypeptide (PACAP1-27), a member of the vasoactive intestinal peptide (VIP) family, VIP1-28, VIP10-28 and VIP1-12 were examined to determine whether they have ameliorative effects on impaired performance caused by scopolamine in a radial-arm maze in rats. In addition, the N-terminal three-amino acid sequence (VIP1-3) shared by PACAP and VIP was tested. Single intraperitoneal (i.p.) injections of PACAP1-27, VIP1-28, VIP1-12 and VIP1-3 and showed ameliorative effects on impaired performance, whereas VIP10-28 did not. The N-terminal three-amino acid sequence was essential for the ameliorative effects. PACAP1-27, VIP1-28, VIP1-12 and VIP1-3, but not VIP10-28, caused increases in the ChAT activity in the medial septum, but not in the diagonal band, caudate and hippocampus. The increase in the ChAT activity produced by VIP, PACAP and their peptide fragments in the medial septum is discussed in relation to their ameliorative effects on scopolamine-induced spatial cognitive impairment.


Copyright © Neuroendocrinology Letters 1997
All rights reserved. No part may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or ortherwise, without prior written permission from the Editor-in-Chief